Cover Image
市場調查報告書

市場上法布瑞氏症的患病人數的預測:2015-2025年主要8國

Fabry Disease Forecast In 8 Major Markets 2015 -2025

出版商 Black Swan Analysis 商品編碼 344276
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
市場上法布瑞氏症的患病人數的預測:2015-2025年主要8國 Fabry Disease Forecast In 8 Major Markets 2015 -2025
出版日期: 2015年10月29日 內容資訊: 英文 42 Pages
簡介

法布瑞氏症是由於存在於長臂X染色體(Xq22)Xq22.1的α-garakutoshidazeA (αGLA) 遺傳基因異常所引起的溶小體儲積症。

本報告提供主要8國市場 (美國·法國·德國·義大利·西班牙·英國·巴西·日本) 的法布瑞氏症的目前患者數 (性別·年齡世代) ,與目前患病人數,疾病概要,危險因素,疾病診斷預後,主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:地區/各民族

疾病預後和臨床過程

疾病相關的主要併發症狀/特徵

患者數的定量化手法

法布瑞氏症的患病人數:各國

法布瑞氏症造成的聽力障礙

  • 聽力障礙的類型
  • 聽力障礙的程度

相關的併發症狀

  • 腎及尿道障礙
  • 心血管系統的症狀
  • 皮膚的狀態
  • 眼睛症狀

用語·簡稱

其他的出版物

線上資料庫

線上價格資料&平台

參考文獻

附錄

目錄
Product Code: FABR0011015

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (αGLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

  • Angiokeratoma
  • Cornea verticillata (corneal whorling)
  • Hearing loss
  • Tinnitus
  • Proteinurea
  • Cardiac hypertrophy & arrhythmias
  • Sweating dysfunction

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Fabry disease's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Fabry disease and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Fabry disease's prevalent population.
  • Identify sub-populations within Fabry Disease which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Fabry disease patients.

Coverage

  • U.S.
  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Japan
  • Brazil

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis &Clinical Course
  • Key Co-morbid Conditions /Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Fabry Disease
  • Hearing Loss in Fabry Disease
    • Type of Hearing Loss
    • Extent of Hearing Loss
  • Associated Co-morbid Conditions of Fabry Disease
    • Renal & Urinary Conditions
    • Cardiovascular Affected Conditions
    • Dermatological Conditions
    • Ophthalmic Conditions
  • Abbreviations and Acronyms used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • WHO criteria for hearing impairment
  • Prevalence of Angina, total (000s)
  • Prevalence of Angina, males (000s)
  • Prevalence of Angina, females (000s)
  • Type of hearing loss in patients with Fabry disease, total (000s)
  • Extent of hearing loss in patients with Fabry disease, total (000s)
  • Prevalence of renal/urinary symptoms in patients with Fabry disease, total (000s)
  • Renal/urinary incompetence in patients with Fabry disease, total (000s)
  • Cardiac symptoms in patients with Fabry disease, total (000s)
  • Heart conditions in patients with Fabry disease, total (000s)
  • Dermatological symptoms in patients with Fabry disease, total (000s)
  • Sweat disorders in patients with Fabry disease, total (000s)
  • Capillary skin disorders in patients with Fabry disease, total (000s)
  • Ocular symptoms in patients with Fabry disease, total (000s)
  • Ocular conditions in patients with Fabry disease, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • USA Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • France Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • France Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • Germany Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • Germany Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • Italy Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • Italy Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • Spain Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • Spain Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
  • Japan Prevalence of Fabry Disease by 5-yr age cohort, males (000s)
  • Japan Prevalence of Fabry Disease by 5-yr age cohort, females (000s)
Back to Top